Followers | 237 |
Posts | 10817 |
Boards Moderated | 0 |
Alias Born | 07/17/2006 |
![](https://investorshub.advfn.com/uicon/76999.png?cb=1549903350)
Tuesday, May 26, 2020 1:24:13 PM
Americans for Pharmaceutical Relief Act
America must strive for innovation and leadership in the field of medicine and pharmaceuticals. The Hatch-Waxman act, while well intended has actually increased pharmaceutical expense and risk to innovation. This places American lives in jeopardy. A pharmaceutical company can file and receive a patent(s) from the USPTO and complete an expensive clinical trial where hundreds of millions of dollars are spent to prove the safety and efficacy of the drug. According to an MIT study, only 14% of drugs taken through clinical trials receive regulatory approval. If a drug is approved in the US, foreign generic suppliers can apply for approval to the FDA under Hatch-Waxman and the pharmaceutical that invented the drug, bore the expense of the clinical trial must defend the patent in court or have their innovation stolen by the foreign generic. To avoid a trial, many pharmaceuticals settle with the generic company and that cost is passed to consumers. Companies settle rather than run the risk that judicial activism can strip them of their innovation. Those that do go through trial must pass the cost to consumers. The cost, and risk to a pharmaceutical hinders innovation and increases the cost to consumers. The act is a means to bolster Hatch-Waxman by providing innovators alternatives that resemble some of the regulations in Europe."
I don't speak Lawyereze..but this paragraph sounds very strong to me. It is said if you wish to call up a demon: you must first learn his name..In this case I see many names "stupidity" (on the part of Du) There is an old saying; "Nothing is as frightening as ignorance in action."is Du really all we have in the Judiciary. An affirmative action example of how someone exists in the murky ground that separates the law from politics. "Connected" I believe is the word..Interestingly enough it has the same meaning in La Cosa Nostra...The word I am looking at is Arrogance..The most amazing thing to me is how this women who was not even born in the USA can boldly put herself in front of both the FDA and USPTO and say she knows more about drugs and patents than they do put together..when it is clear she is incapable of even reading a Medical Journal and getting her information correct..
The problem is not with her,,The problem is we let her and her fellow judges run over us because they are wearing black Robes..Is there nobody willing to call Bull Sh*t on this whole charade. This can not be right... Are we all morons that we watch this arrogant bullsh*ter..throw learned opinions out the window because she is a judge. This is not "Justice"..This is farce..
.Why are we wasting billions of dollars running the FDA to evaluate drugs as to their safety and efficacy. If all it really takes to approve a new medication is an an OK by Judge Du. Why do we need a patent office stuffed with expert when Du the almighty can throw six or seven patents out with a wave of her arm and wink of her eye..Why are we blowing all that money when the solution is so clear...
Why are we putting up with this..are we that brainless...I'd like to see these judges pass a state medical licence exam. Before they made such momentous decisions..Barring that..I feel they are stealing my money and are nothing more than thieves in black robes..It.s a con game and we are all the dupes...
":>) JL
Recent AMRN News
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 11:30:10 AM
- Amarin Board of Directors Announces CEO Transition • GlobeNewswire Inc. • 06/04/2024 11:30:00 AM
- Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Greece and Announces Exclusive Marketing and Commercialization Agreement with Vianex S.A. • GlobeNewswire Inc. • 05/28/2024 12:15:23 PM
- Amarin to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference • GlobeNewswire Inc. • 05/06/2024 12:00:00 PM
- Amarin Reports First Quarter 2024 Business Update and Financial Results • GlobeNewswire Inc. • 05/01/2024 11:00:00 AM
- Amarin Applauds HealthyWomen’s Citizen’s Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular Event • GlobeNewswire Inc. • 04/24/2024 06:00:01 PM
- Amarin Announces Results of Annual General Meeting of Shareholders • GlobeNewswire Inc. • 04/22/2024 12:00:25 PM
- Amarin to Report First Quarter 2024 Financial Results and Host Conference Call on May 1, 2024 • GlobeNewswire Inc. • 04/15/2024 12:00:00 PM
- Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24 • GlobeNewswire Inc. • 04/08/2024 12:00:00 PM
- New REDUCE-IT® Analyses Show VASCEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups • PR Newswire (Canada) • 04/08/2024 10:30:00 AM
- New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups • GlobeNewswire Inc. • 04/06/2024 07:30:00 PM
- Amarin Provides Update on VAZKEPA® (Icosapent Ethyl) Intellectual Property Portfolio in Europe • GlobeNewswire Inc. • 04/03/2024 12:00:00 PM
- Research Evaluating Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the American College of Cardiology’s (ACC) Annual Scientific Session & Expo • GlobeNewswire Inc. • 03/25/2024 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 03/04/2024 10:30:53 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 03/04/2024 01:00:24 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/29/2024 12:06:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/29/2024 12:05:56 PM
- Amarin Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update • GlobeNewswire Inc. • 02/29/2024 12:00:00 PM
- Amarin to Report Fourth Quarter and Full Year 2023 Financial Results and Host Conference on February 29, 2024 • GlobeNewswire Inc. • 02/15/2024 01:00:00 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 02/12/2024 01:00:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 09:31:50 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 09:30:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 09:30:12 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 09:30:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 09:30:22 PM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM